###begin article-title 0
TNF-alpha and sICAM-1 in intracranial aneurismal rupture
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
###xml 544 551 <span type="species:ncbi:9606">patient</span>
Subarachnoidal hemorrhage (SAH) occurring after aneurismal rupture produces an inflammatory response in the cerebral circulation. Tumor necrosis factor (TNF)-alpha is a major cytokine in this process. Adhesion molecules provide information on inflammatory reactions taking place in the walls of blood vessels. Clinical evidence suggests a role of soluble intercellular adhesion molecule (sICAM)-1 in early hemorrhagic events. This study aimed to evaluate the implementation of early TNF-alpha and sICAM-1 serum measurement for the prognosis of patient outcome after intracranial aneurismal rupture.
###end p 2
###begin title 3
Materials and Methods
###end title 3
###begin p 4
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
The study consisted of 27 patients with a diagnosis of intracranial aneurysm. SAH was evaluated on admission according to the Fisher scale, patients-consciousness with the Glasgow Coma Scale, clinical grading with the Hunt and Hess scale, and clinical outcome with the Glasgow Outcome Scale (GOS). Blood samples were drawn within 72 h after arrival at the emergency room. Serum concentrations of TNF-alpha and sICAM-1 were assayed with the ELISA method.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 267 274 <span type="species:ncbi:9606">patient</span>
The initial serum TNF-alpha concentration in the aneurismal patients was low and did not correlate with radiological and clinical scores. The serum sICAM-1 level positively correlated with the severity of bleeding assessed by the Fisher scale and negatively with the patient's scoring in the GOS.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 231 239 <span type="species:ncbi:9606">patients</span>
This study demonstrated the absence of a systemic TNF-alpha-mediated inflammatory response at the onset of subarachnoid hemorrhage. Early measurement of serum sICAM-1 levels offers a potential prognostic value in the assessment of patients-outcome after brain aneurismal rupture.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 102 120 102 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">Selman et al. 2000</xref>
###xml 191 207 191 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">Raps et al. 1993</xref>
###xml 354 373 354 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">Inagawa et al. 1995</xref>
###xml 474 492 474 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">Rinkel et al. 1998</xref>
###xml 620 645 620 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">De Braekeleer et al. 1996</xref>
###xml 647 669 647 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">Wardlaw and White 2000</xref>
###xml 821 843 821 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">Wardlaw and White 2000</xref>
###xml 939 958 939 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">Isaksen et al. 2002</xref>
###xml 1032 1054 1032 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">Wardlaw and White 2000</xref>
###xml 846 852 <span type="species:ncbi:13443">Coffee</span>
Intracranial aneurysms are often defined as weakened, abnormally dilated walls of the major arteries (Selman et al. 2000). The aneurysm is usually asymptomatic for a long time until rupture (Raps et al. 1993). A consequence of an aneurismal wall burst is blood leakage into the cerebral structures, which may lead to irreversible brain damage and death (Inagawa et al. 1995). The incidence of intracranial aneurismal in the general population is estimated to be about 4-6% (Rinkel et al. 1998). Inherited syndromes, traumatic or infectious diseases, and behavioral influences have been specified among the risk factors (De Braekeleer et al. 1996; Wardlaw and White 2000). Subjects of female gender, aged over 50, hypertensive, hypercholesterolemic, or with a current smoking history are prone to develop brain aneurysms (Wardlaw and White 2000). Coffee consumption may increase the incidence of aneurismal subarachnoidal hemorrhage (SAH) (Isaksen et al. 2002). The potential influence of alcohol consumption is under investigation (Wardlaw and White 2000).
###end p 11
###begin p 12
###xml 140 162 140 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">Fassbender et al. 2001</xref>
###xml 164 184 164 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">Takizawa et al. 2001</xref>
###xml 493 511 489 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">Dumont et al. 2003</xref>
###xml 513 534 509 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">Hirashima et al. 1997</xref>
###xml 464 471 <span type="species:ncbi:9606">patient</span>
SAH occurring after aneurismal rupture produces an inflammatory response in the cerebral circulation mediated by proinflammatory cytokines (Fassbender et al. 2001; Takizawa et al. 2001). Tumor necrosis factor (TNF)-alpha is one of the key immune activators of leukocytes counteracting the underlying pathological condition. Stimulated by cytokines, the inflammatory process may promote the development of cerebral vasospasm and ischemia, which negatively affect a patient's outcome after SAH (Dumont et al. 2003; Hirashima et al. 1997).
###end p 12
###begin p 13
###xml 108 122 108 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">Witkowska 2005</xref>
###xml 437 454 437 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">Mocco et al. 2002</xref>
###xml 553 569 553 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">Mack et al. 2002</xref>
Adhesion molecules provide information on inflammatory reactions which occur in the walls of blood vessels (Witkowska 2005). Soluble intercellular adhesion molecule (sICAM)-1 is a circulating form of ICAM-1, a molecule that is crucial for leukocyte adhesion to endothelial cells in the process of leukocyte migration through the vessel's wall. Clinical evidence suggests that sICAM-1 may be engaged in the process of cerebral vasospasm (Mocco et al. 2002), and late elevated levels of serum sICAM-1 were predictors of poor outcome after aneurismal SAH (Mack et al. 2002).
###end p 13
###begin p 14
###xml 164 186 164 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">Dhar and Diringer 2008</xref>
###xml 188 206 188 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">Dumont et al. 2003</xref>
###xml 144 151 <span type="species:ncbi:9606">patient</span>
Inflammatory cytokines and adhesion molecules may contribute to complications after intracranial hemorrhage, with dramatic consequences for the patient's survival (Dhar and Diringer 2008; Dumont et al. 2003). Hence this study aimed to evaluate the relationships between early TNF-alpha and sICAM-1 serum levels and prognosis after aneurismal rupture.
###end p 14
###begin title 15
Materials and Methods
###end title 15
###begin p 16
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 411 418 411 418 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</label>
###xml 418 432 418 432 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Patients&#8217; data</p>
###xml 418 432 418 432 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Patients&#8217; data</p></caption>
###xml 432 449 432 449 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (male/female)</td>
###xml 449 454 449 454 <td xmlns:xlink="http://www.w3.org/1999/xlink">14/13</td>
###xml 432 454 432 454 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (male/female)</td><td>14/13</td></tr>
###xml 454 480 454 480 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years) &#8212; mean (range)</td>
###xml 480 490 480 490 <td xmlns:xlink="http://www.w3.org/1999/xlink">56 (33&#8211;77)</td>
###xml 454 490 454 490 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years) &#8212; mean (range)</td><td>56 (33&#8211;77)</td></tr>
###xml 490 529 490 529 <td xmlns:xlink="http://www.w3.org/1999/xlink">Deaths/survivals after aneurysm rupture</td>
###xml 529 533 529 533 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/22</td>
###xml 490 533 490 533 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Deaths/survivals after aneurysm rupture</td><td>5/22</td></tr>
###xml 533 563 533 563 <td xmlns:xlink="http://www.w3.org/1999/xlink">Body mass index &#8212; mean (range)</td>
###xml 563 573 563 573 <td xmlns:xlink="http://www.w3.org/1999/xlink">28 (21&#8211;42)</td>
###xml 533 573 533 573 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body mass index &#8212; mean (range)</td><td>28 (21&#8211;42)</td></tr>
###xml 573 620 573 620 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cigarette smokers/nonsmokers/data not available</td>
###xml 620 626 620 626 <td xmlns:xlink="http://www.w3.org/1999/xlink">8/9/10</td>
###xml 573 626 573 626 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Cigarette smokers/nonsmokers/data not available</td><td>8/9/10</td></tr>
###xml 626 745 626 743 <td xmlns:xlink="http://www.w3.org/1999/xlink">Alcohol drinkers (spirits &#8805;3 times/week)/occasional drinkers (spirits &lt;3 times/week) or abstainers/data not available</td>
###xml 745 751 743 749 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/17/9</td>
###xml 626 751 626 749 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Alcohol drinkers (spirits &#8805;3 times/week)/occasional drinkers (spirits &lt;3 times/week) or abstainers/data not available</td><td>0/17/9</td></tr>
###xml 751 880 749 876 <td xmlns:xlink="http://www.w3.org/1999/xlink">Coffee drinkers (coffee consumption &#8805;3 times/week)/occasional coffee drinkers (&lt;3 times/week) or nondrinkers/data not available</td>
###xml 880 886 876 882 <td xmlns:xlink="http://www.w3.org/1999/xlink">9/8/10</td>
###xml 751 886 749 882 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Coffee drinkers (coffee consumption &#8805;3 times/week)/occasional coffee drinkers (&lt;3 times/week) or nondrinkers/data not available</td><td>9/8/10</td></tr>
###xml 432 886 432 882 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Sex (male/female)</td><td>14/13</td></tr><tr><td>Age (years) &#8212; mean (range)</td><td>56 (33&#8211;77)</td></tr><tr><td>Deaths/survivals after aneurysm rupture</td><td>5/22</td></tr><tr><td>Body mass index &#8212; mean (range)</td><td>28 (21&#8211;42)</td></tr><tr><td>Cigarette smokers/nonsmokers/data not available</td><td>8/9/10</td></tr><tr><td>Alcohol drinkers (spirits &#8805;3 times/week)/occasional drinkers (spirits &lt;3 times/week) or abstainers/data not available</td><td>0/17/9</td></tr><tr><td>Coffee drinkers (coffee consumption &#8805;3 times/week)/occasional coffee drinkers (&lt;3 times/week) or nondrinkers/data not available</td><td>9/8/10</td></tr></tbody>
###xml 432 886 432 882 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><tbody><tr><td>Sex (male/female)</td><td>14/13</td></tr><tr><td>Age (years) &#8212; mean (range)</td><td>56 (33&#8211;77)</td></tr><tr><td>Deaths/survivals after aneurysm rupture</td><td>5/22</td></tr><tr><td>Body mass index &#8212; mean (range)</td><td>28 (21&#8211;42)</td></tr><tr><td>Cigarette smokers/nonsmokers/data not available</td><td>8/9/10</td></tr><tr><td>Alcohol drinkers (spirits &#8805;3 times/week)/occasional drinkers (spirits &lt;3 times/week) or abstainers/data not available</td><td>0/17/9</td></tr><tr><td>Coffee drinkers (coffee consumption &#8805;3 times/week)/occasional coffee drinkers (&lt;3 times/week) or nondrinkers/data not available</td><td>9/8/10</td></tr></tbody></table>
###xml 411 886 411 882 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p textid="17">Patients&#8217; data</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Sex (male/female)</td><td>14/13</td></tr><tr><td>Age (years) &#8212; mean (range)</td><td>56 (33&#8211;77)</td></tr><tr><td>Deaths/survivals after aneurysm rupture</td><td>5/22</td></tr><tr><td>Body mass index &#8212; mean (range)</td><td>28 (21&#8211;42)</td></tr><tr><td>Cigarette smokers/nonsmokers/data not available</td><td>8/9/10</td></tr><tr><td>Alcohol drinkers (spirits &#8805;3 times/week)/occasional drinkers (spirits &lt;3 times/week) or abstainers/data not available</td><td>0/17/9</td></tr><tr><td>Coffee drinkers (coffee consumption &#8805;3 times/week)/occasional coffee drinkers (&lt;3 times/week) or nondrinkers/data not available</td><td>9/8/10</td></tr></tbody></table></table-wrap>
###xml 77 89 <span type="species:ncbi:9606">participants</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 768 774 <span type="species:ncbi:13443">coffee</span>
###xml 815 821 <span type="species:ncbi:13443">coffee</span>
The protocol of the study was approved by the local bioethics committee. The participants were 27 patients with a diagnosis of ruptured intracranial aneurysm admitted to the Department of Neurosurgery for life-saving surgery. Their detailed data are shown in Table 1. Seventeen healthy subjects of both genders, aged between 38-71 years (mean age: 55 years), took part in the examinations as the control group. Table 1Patients' dataSex (male/female)14/13Age (years) - mean (range)56 (33-77)Deaths/survivals after aneurysm rupture5/22Body mass index - mean (range)28 (21-42)Cigarette smokers/nonsmokers/data not available8/9/10Alcohol drinkers (spirits >/=3 times/week)/occasional drinkers (spirits <3 times/week) or abstainers/data not available0/17/9Coffee drinkers (coffee consumption >/=3 times/week)/occasional coffee drinkers (<3 times/week) or nondrinkers/data not available9/8/10
###end p 16
###begin p 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' data
###end p 17
###begin p 18
###xml 99 117 99 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">Fisher et al. 1980</xref>
###xml 194 219 194 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">Teasdale and Jennett 1974</xref>
###xml 283 301 283 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">Hunt and Hess 1968</xref>
###xml 542 563 542 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">Jennett and Bond 1975</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
SAH was evaluated on admission using computed tomography and graded according to the Fisher scale (Fisher et al. 1980). The patients' consciousness was graded with the Glasgow Coma Scale (GCS) (Teasdale and Jennett 1974). Clinical grading was performed with the Hunt and Hess scale (Hunt and Hess 1968). Grading with the Fisher scale, GCS, and Hunt and Hess scale was available for 24 patients (the other 3 patients died before clinical assessment). Clinical outcome of the patients was assessed according to the Glasgow Outcome Scale (GOS) (Jennett and Bond 1975).
###end p 18
###begin p 19
Venous blood samples were drawn within 72 h after arrival at the emergency room. Blood was collected into Vacutainer System test tubes containing a clotting activator (Becton Dickinson, France). The samples were allowed to clot for 30 min. After 10-minute centrifugation at an relative centrifugal force of 1000 g, the serum was pipetted into Eppendorf test tubes and kept frozen at -20 C. The serum samples were thawed and assayed for TNF-alpha and sICAM-1 concentrations with commercially available sandwich ELISA (Bender MedSystems Diagnostics GmbH, Vienna, Austria) according to the manufacturer's directions.
###end p 19
###begin p 20
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Statistical calculations were based on parametric tests. Group comparisons were performed using Student's t-test. Correlation of radiological and clinical grading with the serum TNF-alpha and sICAM-1 concentrations was made with Pearson's test. A probability level of 5% was considered statistically significant. Statistica 6.1 software (StatSoft, Inc.) was implemented for data analysis.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 541 548 541 548 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 2</label>
###xml 548 591 548 591 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Patients&#8217; radiological and clinical grading</p>
###xml 548 591 548 591 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Patients&#8217; radiological and clinical grading</p></caption>
###xml 591 596 591 596 <th xmlns:xlink="http://www.w3.org/1999/xlink">Grade</th>
###xml 596 614 596 614 <th xmlns:xlink="http://www.w3.org/1999/xlink">Fisher scale n (%)</th>
###xml 614 623 614 623 <th xmlns:xlink="http://www.w3.org/1999/xlink">GCS n (%)</th>
###xml 623 648 623 648 <th xmlns:xlink="http://www.w3.org/1999/xlink">Hunt and Hess scale n (%)</th>
###xml 648 657 648 657 <th xmlns:xlink="http://www.w3.org/1999/xlink">GOS n (%)</th>
###xml 591 657 591 657 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Grade</th><th>Fisher scale n (%)</th><th>GCS n (%)</th><th>Hunt and Hess scale n (%)</th><th>GOS n (%)</th></tr>
###xml 591 657 591 657 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Grade</th><th>Fisher scale n (%)</th><th>GCS n (%)</th><th>Hunt and Hess scale n (%)</th><th>GOS n (%)</th></tr></thead>
###xml 657 658 657 658 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 658 659 658 659 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 659 660 659 660 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 660 668 660 668 <td xmlns:xlink="http://www.w3.org/1999/xlink">6 (22.2)</td>
###xml 668 669 668 669 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 657 669 657 669 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>0</td><td>&#8211;</td><td>&#8211;</td><td>6 (22.2)</td><td>&#8211;</td></tr>
###xml 669 670 669 670 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 670 678 670 678 <td xmlns:xlink="http://www.w3.org/1999/xlink">6 (22.2)</td>
###xml 678 679 678 679 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 679 688 679 688 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (51.9)</td>
###xml 688 696 688 696 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (18.5)</td>
###xml 669 696 669 696 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>1</td><td>6 (22.2)</td><td>0</td><td>14 (51.9)</td><td>5 (18.5)</td></tr>
###xml 696 697 696 697 <td xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 697 705 697 705 <td xmlns:xlink="http://www.w3.org/1999/xlink">8 (29.6)</td>
###xml 705 706 705 706 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 706 707 706 707 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 707 708 707 708 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 696 708 696 708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>2</td><td>8 (29.6)</td><td>0</td><td>0</td><td>0</td></tr>
###xml 708 709 708 709 <td xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 709 717 709 717 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (18.5)</td>
###xml 717 718 717 718 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 718 725 718 725 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (7.4)</td>
###xml 725 732 725 732 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (7.4)</td>
###xml 708 732 708 732 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>3</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>2 (7.4)</td></tr>
###xml 732 733 732 733 <td xmlns:xlink="http://www.w3.org/1999/xlink">4</td>
###xml 733 741 733 741 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (18.5)</td>
###xml 741 742 741 742 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 742 749 742 749 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (7.4)</td>
###xml 749 757 749 757 <td xmlns:xlink="http://www.w3.org/1999/xlink">7 (25.9)</td>
###xml 732 757 732 757 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>4</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>7 (25.9)</td></tr>
###xml 757 758 757 758 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 758 759 758 759 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 759 760 759 760 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 760 761 760 761 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 761 770 761 770 <td xmlns:xlink="http://www.w3.org/1999/xlink">13 (48.1)</td>
###xml 757 770 757 770 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>&#8211;</td><td>0</td><td>0</td><td>13 (48.1)</td></tr>
###xml 770 771 770 771 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 771 772 771 772 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 772 773 772 773 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 773 774 773 774 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 774 775 774 775 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 770 775 770 775 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 775 776 775 776 <td xmlns:xlink="http://www.w3.org/1999/xlink">7</td>
###xml 776 777 776 777 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 777 778 777 778 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 778 779 778 779 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 779 780 779 780 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 775 780 775 780 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>7</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 780 781 780 781 <td xmlns:xlink="http://www.w3.org/1999/xlink">8</td>
###xml 781 782 781 782 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 782 783 782 783 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 783 784 783 784 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 784 785 784 785 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 780 785 780 785 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>8</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 785 786 785 786 <td xmlns:xlink="http://www.w3.org/1999/xlink">9</td>
###xml 786 787 786 787 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 787 788 787 788 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 788 789 788 789 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 789 790 789 790 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 785 790 785 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>9</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 790 792 790 792 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 792 793 792 793 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 793 794 793 794 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 794 795 794 795 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 795 796 795 796 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 790 796 790 796 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>10</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 796 798 796 798 <td xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 798 799 798 799 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 799 806 799 806 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (3.7)</td>
###xml 806 807 806 807 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 807 808 807 808 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 796 808 796 808 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>11</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 808 810 808 810 <td xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 810 811 810 811 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 811 812 811 812 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 812 813 812 813 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 813 814 813 814 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 808 814 808 814 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>12</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 814 816 814 816 <td xmlns:xlink="http://www.w3.org/1999/xlink">13</td>
###xml 816 817 816 817 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 817 825 817 825 <td xmlns:xlink="http://www.w3.org/1999/xlink">4 (14.8)</td>
###xml 825 826 825 826 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 826 827 826 827 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 814 827 814 827 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>13</td><td>&#8211;</td><td>4 (14.8)</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 827 829 827 829 <td xmlns:xlink="http://www.w3.org/1999/xlink">14</td>
###xml 829 830 829 830 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 830 837 830 837 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (3.7)</td>
###xml 837 838 837 838 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 838 839 838 839 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 827 839 827 839 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>14</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 839 841 839 841 <td xmlns:xlink="http://www.w3.org/1999/xlink">15</td>
###xml 841 842 841 842 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 842 851 842 851 <td xmlns:xlink="http://www.w3.org/1999/xlink">18 (66.7)</td>
###xml 851 852 851 852 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 852 853 852 853 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 839 853 839 853 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>15</td><td>&#8211;</td><td>18 (66.7)</td><td>&#8211;</td><td>&#8211;</td></tr>
###xml 657 853 657 853 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>0</td><td>&#8211;</td><td>&#8211;</td><td>6 (22.2)</td><td>&#8211;</td></tr><tr><td>1</td><td>6 (22.2)</td><td>0</td><td>14 (51.9)</td><td>5 (18.5)</td></tr><tr><td>2</td><td>8 (29.6)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>3</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>2 (7.4)</td></tr><tr><td>4</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>7 (25.9)</td></tr><tr><td>5</td><td>&#8211;</td><td>0</td><td>0</td><td>13 (48.1)</td></tr><tr><td>6</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>7</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>8</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>9</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>10</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>11</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>12</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>13</td><td>&#8211;</td><td>4 (14.8)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>14</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15</td><td>&#8211;</td><td>18 (66.7)</td><td>&#8211;</td><td>&#8211;</td></tr></tbody>
###xml 591 853 591 853 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Grade</th><th>Fisher scale n (%)</th><th>GCS n (%)</th><th>Hunt and Hess scale n (%)</th><th>GOS n (%)</th></tr></thead><tbody><tr><td>0</td><td>&#8211;</td><td>&#8211;</td><td>6 (22.2)</td><td>&#8211;</td></tr><tr><td>1</td><td>6 (22.2)</td><td>0</td><td>14 (51.9)</td><td>5 (18.5)</td></tr><tr><td>2</td><td>8 (29.6)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>3</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>2 (7.4)</td></tr><tr><td>4</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>7 (25.9)</td></tr><tr><td>5</td><td>&#8211;</td><td>0</td><td>0</td><td>13 (48.1)</td></tr><tr><td>6</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>7</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>8</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>9</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>10</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>11</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>12</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>13</td><td>&#8211;</td><td>4 (14.8)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>14</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15</td><td>&#8211;</td><td>18 (66.7)</td><td>&#8211;</td><td>&#8211;</td></tr></tbody></table>
###xml 853 876 853 876 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">n &#8211; number of patients.</p>
###xml 853 876 853 876 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">n &#8211; number of patients.</p></table-wrap-foot>
###xml 541 876 541 876 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p textid="23">Patients&#8217; radiological and clinical grading</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Grade</th><th>Fisher scale n (%)</th><th>GCS n (%)</th><th>Hunt and Hess scale n (%)</th><th>GOS n (%)</th></tr></thead><tbody><tr><td>0</td><td>&#8211;</td><td>&#8211;</td><td>6 (22.2)</td><td>&#8211;</td></tr><tr><td>1</td><td>6 (22.2)</td><td>0</td><td>14 (51.9)</td><td>5 (18.5)</td></tr><tr><td>2</td><td>8 (29.6)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>3</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>2 (7.4)</td></tr><tr><td>4</td><td>5 (18.5)</td><td>0</td><td>2 (7.4)</td><td>7 (25.9)</td></tr><tr><td>5</td><td>&#8211;</td><td>0</td><td>0</td><td>13 (48.1)</td></tr><tr><td>6</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>7</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>8</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>9</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>10</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>11</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>12</td><td>&#8211;</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>13</td><td>&#8211;</td><td>4 (14.8)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>14</td><td>&#8211;</td><td>1 (3.7)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>15</td><td>&#8211;</td><td>18 (66.7)</td><td>&#8211;</td><td>&#8211;</td></tr></tbody></table><table-wrap-foot><p textid="24">n &#8211; number of patients.</p></table-wrap-foot></table-wrap>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 867 875 <span type="species:ncbi:9606">patients</span>
The patients' clinical presentation and radiological assessment by computed tomography are shown in Table 2. On admission, 67% of the subjects showed signs of cerebral bleeding of different degrees (grades 2-4 on the Fisher scale). The patients' grading according to the GCS was between 11 and 15. Seventy-four percent of the patients presented with grades 0-1 on the Hunt and Hess scale. The patients' rating on the GOS was between 3 and 5 for 81% of the subjects. The death rate was about 19% (5 patients died during the hospitalization). Table 2Patients' radiological and clinical gradingGradeFisher scale n (%)GCS n (%)Hunt and Hess scale n (%)GOS n (%)0--6 (22.2)-16 (22.2)014 (51.9)5 (18.5)28 (29.6)00035 (18.5)02 (7.4)2 (7.4)45 (18.5)02 (7.4)7 (25.9)5-0013 (48.1)6-0--7-0--8-0--9-0--10-0--11-1 (3.7)--12-0--13-4 (14.8)--14-1 (3.7)--15-18 (66.7)--n - number of patients.
###end p 22
###begin p 23
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' radiological and clinical grading
###end p 23
###begin p 24
###xml 14 22 <span type="species:ncbi:9606">patients</span>
n - number of patients.
###end p 24
###begin p 25
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 241 248 237 244 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 3</label>
###xml 248 355 244 345 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Serum TNF-&#945; and sICAM-1 concentrations (mean&#177;SD) in patients with intracranial aneurysms vs. controls</p>
###xml 248 355 244 345 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Serum TNF-&#945; and sICAM-1 concentrations (mean&#177;SD) in patients with intracranial aneurysms vs. controls</p></caption>
###xml 355 355 345 345 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 355 384 345 374 <th xmlns:xlink="http://www.w3.org/1999/xlink">Intracranial aneurysms (n=27)</th>
###xml 384 399 374 389 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls (n=17)</th>
###xml 399 406 389 396 <th xmlns:xlink="http://www.w3.org/1999/xlink">p-value</th>
###xml 355 406 345 396 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Intracranial aneurysms (n=27)</th><th>Controls (n=17)</th><th>p-value</th></tr>
###xml 355 406 345 396 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Intracranial aneurysms (n=27)</th><th>Controls (n=17)</th><th>p-value</th></tr></thead>
###xml 406 423 396 409 <td xmlns:xlink="http://www.w3.org/1999/xlink">TNF-&#945; (pg/ml)</td>
###xml 423 435 409 419 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.42&#177;9.70</td>
###xml 435 447 419 429 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.29&#177;8.80</td>
###xml 447 449 429 431 <td xmlns:xlink="http://www.w3.org/1999/xlink">NS</td>
###xml 406 449 396 431 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>TNF-&#945; (pg/ml)</td><td>12.42&#177;9.70</td><td>11.29&#177;8.80</td><td>NS</td></tr>
###xml 449 464 431 446 <td xmlns:xlink="http://www.w3.org/1999/xlink">sICAM-1 (ng/ml)</td>
###xml 464 472 446 452 <td xmlns:xlink="http://www.w3.org/1999/xlink">255&#177;90</td>
###xml 472 480 452 458 <td xmlns:xlink="http://www.w3.org/1999/xlink">225&#177;50</td>
###xml 480 482 458 460 <td xmlns:xlink="http://www.w3.org/1999/xlink">NS</td>
###xml 449 482 431 460 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>sICAM-1 (ng/ml)</td><td>255&#177;90</td><td>225&#177;50</td><td>NS</td></tr>
###xml 406 482 396 460 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>TNF-&#945; (pg/ml)</td><td>12.42&#177;9.70</td><td>11.29&#177;8.80</td><td>NS</td></tr><tr><td>sICAM-1 (ng/ml)</td><td>255&#177;90</td><td>225&#177;50</td><td>NS</td></tr></tbody>
###xml 355 482 345 460 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Intracranial aneurysms (n=27)</th><th>Controls (n=17)</th><th>p-value</th></tr></thead><tbody><tr><td>TNF-&#945; (pg/ml)</td><td>12.42&#177;9.70</td><td>11.29&#177;8.80</td><td>NS</td></tr><tr><td>sICAM-1 (ng/ml)</td><td>255&#177;90</td><td>225&#177;50</td><td>NS</td></tr></tbody></table>
###xml 482 503 460 481 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">NS &#8212; not significant.</p>
###xml 482 503 460 481 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">NS &#8212; not significant.</p></table-wrap-foot>
###xml 241 503 237 481 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p textid="26">Serum TNF-&#945; and sICAM-1 concentrations (mean&#177;SD) in patients with intracranial aneurysms vs. controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Intracranial aneurysms (n=27)</th><th>Controls (n=17)</th><th>p-value</th></tr></thead><tbody><tr><td>TNF-&#945; (pg/ml)</td><td>12.42&#177;9.70</td><td>11.29&#177;8.80</td><td>NS</td></tr><tr><td>sICAM-1 (ng/ml)</td><td>255&#177;90</td><td>225&#177;50</td><td>NS</td></tr></tbody></table><table-wrap-foot><p textid="27">NS &#8212; not significant.</p></table-wrap-foot></table-wrap>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
Comparisons of the parameters tested in the patients with intracranial aneurysms vs. controls are shown in Table 3. No differences in the mean serum TNF-alpha and sICAM-1 concentrations of the aneurismal subjects and controls were observed. Table 3Serum TNF-alpha and sICAM-1 concentrations (mean+/-SD) in patients with intracranial aneurysms vs. controlsIntracranial aneurysms (n=27)Controls (n=17)p-valueTNF-alpha (pg/ml)12.42+/-9.7011.29+/-8.80NSsICAM-1 (ng/ml)255+/-90225+/-50NSNS - not significant.
###end p 25
###begin p 26
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Serum TNF-alpha and sICAM-1 concentrations (mean+/-SD) in patients with intracranial aneurysms vs. controls
###end p 26
###begin p 27
NS - not significant.
###end p 27
###begin p 28
###xml 101 102 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 229 236 225 232 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 4</label>
###xml 236 326 232 318 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Serum TNF-&#945; and sICAM-1 concentrations in relation to radiological and clinical scores</p>
###xml 236 326 232 318 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Serum TNF-&#945; and sICAM-1 concentrations in relation to radiological and clinical scores</p></caption>
###xml 326 331 318 323 <th xmlns:xlink="http://www.w3.org/1999/xlink">Grade</th>
###xml 331 348 323 340 <th xmlns:xlink="http://www.w3.org/1999/xlink">Fisher scale n=24</th>
###xml 348 356 340 348 <th xmlns:xlink="http://www.w3.org/1999/xlink">GCS n=24</th>
###xml 356 380 348 372 <th xmlns:xlink="http://www.w3.org/1999/xlink">Hunt and Hess scale n=24</th>
###xml 380 388 372 380 <th xmlns:xlink="http://www.w3.org/1999/xlink">GOS n=27</th>
###xml 326 388 318 380 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Grade</th><th>Fisher scale n=24</th><th>GCS n=24</th><th>Hunt and Hess scale n=24</th><th>GOS n=27</th></tr>
###xml 326 388 318 380 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Grade</th><th>Fisher scale n=24</th><th>GCS n=24</th><th>Hunt and Hess scale n=24</th><th>GOS n=27</th></tr></thead>
###xml 388 397 380 385 <td xmlns:xlink="http://www.w3.org/1999/xlink">TNF-&#945;</td>
###xml 397 406 385 394 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =&#8722;0.055</td>
###xml 406 414 394 402 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =0.143</td>
###xml 414 423 402 411 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =&#8722;0.042</td>
###xml 423 431 411 419 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =0.077</td>
###xml 388 431 380 419 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>TNF-&#945;</td><td>r =&#8722;0.055</td><td>r =0.143</td><td>r =&#8722;0.042</td><td>r =0.077</td></tr>
###xml 431 431 419 419 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 431 438 419 426 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.799</td>
###xml 438 445 426 433 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.504</td>
###xml 445 452 433 440 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.846</td>
###xml 452 459 440 447 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.722</td>
###xml 431 459 419 447 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>p=0.799</td><td>p=0.504</td><td>p=0.846</td><td>p=0.722</td></tr>
###xml 459 466 447 454 <td xmlns:xlink="http://www.w3.org/1999/xlink">sICAM-1</td>
###xml 466 474 454 462 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =0.439</td>
###xml 474 483 462 471 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =&#8722;0.191</td>
###xml 483 491 471 479 <td xmlns:xlink="http://www.w3.org/1999/xlink">r =0.376</td>
###xml 491 499 479 487 <td xmlns:xlink="http://www.w3.org/1999/xlink">r=&#8722;0.423</td>
###xml 459 499 447 487 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>sICAM-1</td><td>r =0.439</td><td>r =&#8722;0.191</td><td>r =0.376</td><td>r=&#8722;0.423</td></tr>
###xml 499 499 487 487 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 499 506 487 494 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.032</td>
###xml 506 513 494 501 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.372</td>
###xml 513 520 501 508 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.071</td>
###xml 520 527 508 515 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.039</td>
###xml 499 527 487 515 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>p=0.032</td><td>p=0.372</td><td>p=0.071</td><td>p=0.039</td></tr>
###xml 388 527 380 515 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>TNF-&#945;</td><td>r =&#8722;0.055</td><td>r =0.143</td><td>r =&#8722;0.042</td><td>r =0.077</td></tr><tr><td/><td>p=0.799</td><td>p=0.504</td><td>p=0.846</td><td>p=0.722</td></tr><tr><td>sICAM-1</td><td>r =0.439</td><td>r =&#8722;0.191</td><td>r =0.376</td><td>r=&#8722;0.423</td></tr><tr><td/><td>p=0.032</td><td>p=0.372</td><td>p=0.071</td><td>p=0.039</td></tr></tbody>
###xml 326 527 318 515 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Grade</th><th>Fisher scale n=24</th><th>GCS n=24</th><th>Hunt and Hess scale n=24</th><th>GOS n=27</th></tr></thead><tbody><tr><td>TNF-&#945;</td><td>r =&#8722;0.055</td><td>r =0.143</td><td>r =&#8722;0.042</td><td>r =0.077</td></tr><tr><td/><td>p=0.799</td><td>p=0.504</td><td>p=0.846</td><td>p=0.722</td></tr><tr><td>sICAM-1</td><td>r =0.439</td><td>r =&#8722;0.191</td><td>r =0.376</td><td>r=&#8722;0.423</td></tr><tr><td/><td>p=0.032</td><td>p=0.372</td><td>p=0.071</td><td>p=0.039</td></tr></tbody></table>
###xml 527 550 515 538 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">n &#8212; number of patients.</p>
###xml 550 598 538 586 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Bold letters represent statistical significance.</p>
###xml 527 598 515 586 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">n &#8212; number of patients.</p><p textid="31">Bold letters represent statistical significance.</p></table-wrap-foot>
###xml 229 598 225 586 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table 4</label><caption><p textid="29">Serum TNF-&#945; and sICAM-1 concentrations in relation to radiological and clinical scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Grade</th><th>Fisher scale n=24</th><th>GCS n=24</th><th>Hunt and Hess scale n=24</th><th>GOS n=27</th></tr></thead><tbody><tr><td>TNF-&#945;</td><td>r =&#8722;0.055</td><td>r =0.143</td><td>r =&#8722;0.042</td><td>r =0.077</td></tr><tr><td/><td>p=0.799</td><td>p=0.504</td><td>p=0.846</td><td>p=0.722</td></tr><tr><td>sICAM-1</td><td>r =0.439</td><td>r =&#8722;0.191</td><td>r =0.376</td><td>r=&#8722;0.423</td></tr><tr><td/><td>p=0.032</td><td>p=0.372</td><td>p=0.071</td><td>p=0.039</td></tr></tbody></table><table-wrap-foot><p textid="30">n &#8212; number of patients.</p><p textid="31">Bold letters represent statistical significance.</p></table-wrap-foot></table-wrap>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
The serum TNF-alpha concentration did not correlate with the radiological and clinical scores (Table 4). The concentration of sICAM-1 positively correlated with the Fisher grade (r=0.439) and negatively with the GOS (r= -0.423). Table 4Serum TNF-alpha and sICAM-1 concentrations in relation to radiological and clinical scoresGradeFisher scale n=24GCS n=24Hunt and Hess scale n=24GOS n=27TNF-alphar =-0.055r =0.143r =-0.042r =0.077p=0.799p=0.504p=0.846p=0.722sICAM-1r =0.439r =-0.191r =0.376r=-0.423p=0.032p=0.372p=0.071p=0.039n - number of patients.Bold letters represent statistical significance.
###end p 28
###begin p 29
Serum TNF-alpha and sICAM-1 concentrations in relation to radiological and clinical scores
###end p 29
###begin p 30
###xml 14 22 <span type="species:ncbi:9606">patients</span>
n - number of patients.
###end p 30
###begin p 31
Bold letters represent statistical significance.
###end p 31
###begin p 32
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
Serum sICAM-1 concentration in relation to the Fisher and the GOS grading is shown in Fig. 1. A gradually increasing sICAM-1 concentration in relation to the Fisher score was observed. The patients who scored 4 had significantly elevated serum sICAM-1 levels compared with the controls. The sICAM-1 concentration negatively correlated with the scores obtained from the GOS. The patients who were graded 4 and 5 had low serum sICAM-1 levels, comparable to those of the controls. The patients who scored 1 or 3 had significantly higher sICAM-1 levels than the controls and the patients who scored 5.
###end p 32
###begin p 33
Serum sICAM-1 concentration (means+/-SD) according to the Fisher scale and the Glasgow Outcome Scale (GOS).
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 125 144 125 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">Inagawa et al. 1995</xref>
###xml 570 591 562 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">Mathiesen et al. 1997</xref>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
###xml 1068 1076 <span type="species:ncbi:9606">patients</span>
SAH is a life-threatening consequence of an intracranial aneurysm's rupture, which may be lethal for nearly 50% of patients (Inagawa et al. 1995). Disruption of a cerebral artery causes blood extravasations which may induce cytokine-stimulated immune reactions contributing to the development of cerebral vasospasm and ischemia. Systemic inflammation develops in a few days after hemorrhage. TNF-alpha is a major cytokine in the initiation of inflammatory reactions. Significantly increased TNF-alpha levels in the cerebrospinal fluid were observed 4-10 days after SAH (Mathiesen et al. 1997). In the present study, early TNF-alpha levels were studied. Blood samples were taken from the patients within 72 h after admittance to the hospital. The data analysis showed similar TNF-alpha levels in the aneurysmal patients and controls. No correlation of TNF-alpha levels with the radiological and clinical scores was observed. In many pathological conditions, TNF-alpha stimulates an inflammatory response. The low TNF-alpha levels observed in the sera of the aneurismal patients within three days of hospitalization suggest the absence of systemic inflammation during the early hemorrhagic events.
###end p 35
###begin p 36
###xml 338 356 338 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">Frijns et al. 2006</xref>
###xml 358 374 358 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">Mack et al. 2002</xref>
###xml 376 394 376 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">Nissen et al. 2001</xref>
###xml 487 503 487 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">Mack et al. 2002</xref>
###xml 792 810 792 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">Frijns et al. 2006</xref>
###xml 812 830 812 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">Nissen et al. 2001</xref>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
###xml 721 728 <span type="species:ncbi:9606">patient</span>
###xml 956 963 <span type="species:ncbi:9606">patient</span>
###xml 1270 1278 <span type="species:ncbi:9606">patients</span>
###xml 1411 1419 <span type="species:ncbi:9606">patients</span>
Leukocyte penetration through the blood-brain barrier into the subarachnoidal space is facilitated by adhesion molecules on the surface of endothelial cells. sICAM-1, a released form of the membrane molecule, is present in cerebrospinal fluid and blood. Several studies demonstrated an increase in serum sICAM-1 after aneurismal rupture (Frijns et al. 2006; Mack et al. 2002; Nissen et al. 2001). Interesting observations concerning patients' outcome after SAH were made by Mack et al. (Mack et al. 2002). They observed that sICAM-1 levels were elevated in early hemorrhagic events and that late high sICAM-1 levels were predictors of critical outcome. Several other studies did not find significant associations between patient outcome and serum sICAM-1 levels measured at the onset of SAH (Frijns et al. 2006; Nissen et al. 2001). Contrary to these findings, the results obtained in the present study show associations of early serum sICAM-1 levels with patient outcome after SAH. The serum sICAM-1 concentration correlated with the scores obtained in the Fisher and the GOS. The former results demonstrate a clear connection between serum sICAM-1 concentration and the intensity of bleeding. At the same time, high sICAM-1 had a predictive value of poor outcome. The patients who were graded low in the GOS (1 or 3 points) had significantly elevated sICAM-1 titers compared with the healthy controls and the patients with the best scores.
###end p 36
###begin p 37
###xml 221 228 <span type="species:ncbi:9606">patient</span>
This study demonstrates the absence of a systemic inflammatory TNF-alpha-mediated response at the onset of subarachnoid hemorrhage. Early measurement of serum sICAM-1 levels offers a prognostic value in the assessment of patient outcome after brain aneurismal rupture.
###end p 37
###begin title 38
References
###end title 38
###begin article-title 39
A study of inbreeding and kinship in intracranial aneurysms in the Saguenay Lac-Saint-Jean region (Quebec, Canada)
###end article-title 39
###begin article-title 40
The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage
###end article-title 40
###begin article-title 41
Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation
###end article-title 41
###begin article-title 42
Inflammatory cytokines in subarachnoid hemorrhage: association with abnormal blood flow velocities in basal cerebral arteries
###end article-title 42
###begin article-title 43
Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning
###end article-title 43
###begin article-title 44
Early circulating levels of endothelial cell activation markers in aneurismal sub- arachnoid haemorrhage: associations with cerebral ischaemic events and outcome
###end article-title 44
###begin article-title 45
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with sub- arachnoid hemorrhage
###end article-title 45
###begin article-title 46
Surgical risk as related to time of intervention in the repair of intracranial aneurysms
###end article-title 46
###begin article-title 47
Study of aneurismal subarachnoid hemorrhage in Izumo City, Japan
###end article-title 47
###begin article-title 48
Risk factors for aneurysmal subarachnoid haemorrhage: the Tromso study
###end article-title 48
###begin article-title 49
Assessment of outcome after severe brain damage
###end article-title 49
###begin article-title 50
Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurismal subarachnoid hemorrhage
###end article-title 50
###begin article-title 51
Cerebrospinal fluid interleukin-1 receptor antagonist and TNF-alpha following subarachnoid hemorrhage
###end article-title 51
###begin article-title 52
Ride in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage
###end article-title 52
###begin article-title 53
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurismal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies
###end article-title 53
###begin article-title 54
The clinical spectrum of unruptured intracranial aneurysms
###end article-title 54
###begin article-title 55
Prevalence and risk of rupture of intracranial aneurysms: a systematic review
###end article-title 55
###begin article-title 56
Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage
###end article-title 56
###begin article-title 57
Assessment of coma and impaired consciousness
###end article-title 57
###begin article-title 58
The detection and management of unruptured intracranial aneurysms
###end article-title 58
###begin article-title 59
Soluble ICAM-1: a marker of vascular inflammation and lifestyle
###end article-title 59
###begin title 60
Abbreviations
###end title 60
###begin p 61
enzyme-linked immunosorbent assay
###end p 61
###begin p 62
subarachnoidal hemorrhage
###end p 62
###begin p 63
soluble intercellular adhesion molecule-1
###end p 63
###begin p 64
tumor necrosis factor alpha
###end p 64
###begin p 65
Glasgow Coma Scale
###end p 65
###begin p 66
Glasgow Outcome Scale
###end p 66

